LAM Pharmaceutical, Corp., a biomedical company, has completed its plans for the marketing of its breakthrough wound care product, L.A.M. IPM Wound Gel, the company reported.
L.A.M. IPM Wound Gel is approved for: diabetic ulcers, venous stasis ulcers, pressure ulcers (including bed sores), and debrided wounds.
Besides its unparalleled record in creating a suitable environment for healing to take place (moist with essential enzyme and protein enhancement), L.A.M. IPM Wound Gel has a most significant advantage over other leading products -- economy!
The suggested price of a 10 gram tube (approximately 5 days supply), will be US $55.00.
Distribution specialists are in place to ship and invoice the product to a wide group of potential purchasers including: home health care organizations, Nursing homes, hospital wound care clinics, podiatrists, dermatologists, privately owned wound care clinics, and a significant number of the busiest office-based health care professionals.
Alan Drizen, CEO of LAM Pharmaceutical, Corp., said, "We are most pleased to have scaled-up production, arranged for contract manufacturing under our cognizance, and put a powerful marketing structure in place in such a short time following the approval of L.A.M. IPM Wound Gel (April 15, 2002, FDA Number K020325)."
Drizen went on to say, "We are especially pleased with the work of RxCentric Inc. of New York City, who has created a brilliant first wave mini infomercial for L.A.M. IPM Wound Gel. We are convinced that those health care professionals who view the 5-1/2 minute marketing message will understand the product and appreciate its advantages quickly without taking valuable time away from their busy practices."
In addition, L.A.M. IPM Wound Gel is the first product to be judged 89% effective (clinical trial results available on written request) by leading experts and opinion leaders in the fastest growing area of medicine.